<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32270509</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-4598</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>62</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Muscle &amp; nerve</Title>
          <ISOAbbreviation>Muscle Nerve</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Guidelines on clinical presentation and management of nondystrophic myotonias.</ArticleTitle>
        <Pagination>
          <StartPage>430</StartPage>
          <EndPage>444</EndPage>
          <MedlinePgn>430-444</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.26887</ELocationID>
        <Abstract>
          <AbstractText>The nondystrophic myotonias are rare muscle hyperexcitability disorders caused by gain-of-function mutations in the SCN4A gene or loss-of-function mutations in the CLCN1 gene. Clinically, they are characterized by myotonia, defined as delayed muscle relaxation after voluntary contraction, which leads to symptoms of muscle stiffness, pain, fatigue, and weakness. Diagnosis is based on history and examination findings, the presence of electrical myotonia on electromyography, and genetic confirmation. In the absence of genetic confirmation, the diagnosis is supported by detailed electrophysiological testing, exclusion of other related disorders, and analysis of a variant of uncertain significance if present. Symptomatic treatment with a sodium channel blocker, such as mexiletine, is usually the first step in management, as well as educating patients about potential anesthetic complications.</AbstractText>
          <CopyrightInformation>© 2020 Wiley Periodicals, Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Stunnenberg</LastName>
            <ForeName>Bas C</ForeName>
            <Initials>BC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>LoRusso</LastName>
            <ForeName>Samantha</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Ohio State University Wexner Medical Center, Columbus, Ohio.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arnold</LastName>
            <ForeName>W David</ForeName>
            <Initials>WD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Ohio State University Wexner Medical Center, Columbus, Ohio.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barohn</LastName>
            <ForeName>Richard J</ForeName>
            <Initials>RJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cannon</LastName>
            <ForeName>Stephen C</ForeName>
            <Initials>SC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fontaine</LastName>
            <ForeName>Bertrand</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Assistance Publique-Hôpitaix de Paris, Sorbonne Université, INSERM, Service of Neuro-Myology and UMR 974, Institute of Myology, University Hospital Pitié-Salpêtrière, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Griggs</LastName>
            <ForeName>Robert C</ForeName>
            <Initials>RC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Rochester, Rochester, New York.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hanna</LastName>
            <ForeName>Michael G</ForeName>
            <Initials>MG</Initials>
            <AffiliationInfo>
              <Affiliation>MRC Centre for Neuromuscular Diseases, Department of Neuromuscular diseases, UCL Queen Square Institute of Neurology, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matthews</LastName>
            <ForeName>Emma</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0002-3810-306X</Identifier>
            <AffiliationInfo>
              <Affiliation>MRC Centre for Neuromuscular Diseases, Department of Neuromuscular diseases, UCL Queen Square Institute of Neurology, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meola</LastName>
            <ForeName>Giovanni</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurorehabilitation Sciences, Casa Cura Policlinico, Milan, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sansone</LastName>
            <ForeName>Valeria A</ForeName>
            <Initials>VA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Neurorehabilitation Unit, University of Milan, NEuroMuscular Omnicentre (NEMO), Fondazione Serena Onlus, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Trivedi</LastName>
            <ForeName>Jaya R</ForeName>
            <Initials>JR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology and Neurotherapeutics, UT Southwestern Medical Center, Dallas, Texas.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Engelen</LastName>
            <ForeName>Baziel G M</ForeName>
            <Initials>BGM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vicart</LastName>
            <ForeName>Savine</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Assistance Publique-Hôpitaix de Paris, Sorbonne Université, INSERM, Service of Neuro-Myology and UMR 974, Institute of Myology, University Hospital Pitié-Salpêtrière, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Statland</LastName>
            <ForeName>Jeffrey M</ForeName>
            <Initials>JM</Initials>
            <Identifier Source="ORCID">0000-0003-0790-5315</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 AR042703</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AR063182</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R37 AR042703</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <Agency>AFM</Agency>
            <Country>International</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>05</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Muscle Nerve</MedlineTA>
        <NlmUniqueID>7803146</NlmUniqueID>
        <ISSNLinking>0148-639X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C086321">CLC-1 channel</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002257">Carbonic Anhydrase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018118">Chloride Channels</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D062553">NAV1.4 Voltage-Gated Sodium Channel</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C106251">SCN4A protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D026941">Sodium Channel Blockers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061567">Voltage-Gated Sodium Channel Blockers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1U511HHV4Z</RegistryNumber>
          <NameOfSubstance UI="D008801">Mexiletine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>A6IEZ5M406</RegistryNumber>
          <NameOfSubstance UI="D000069458">Ranolazine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>O3FX965V0I</RegistryNumber>
          <NameOfSubstance UI="D000086">Acetazolamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>U3H27498KS</RegistryNumber>
          <NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C538353">Potassium aggravated myotonia</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086" MajorTopicYN="N">Acetazolamide</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002257" MajorTopicYN="N">Carbonic Anhydrase Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018118" MajorTopicYN="N">Chloride Channels</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004568" MajorTopicYN="N">Electrodiagnosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008801" MajorTopicYN="N">Mexiletine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018908" MajorTopicYN="N">Muscle Weakness</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063806" MajorTopicYN="N">Myalgia</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009224" MajorTopicYN="N">Myotonia Congenita</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020967" MajorTopicYN="N">Myotonic Disorders</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062553" MajorTopicYN="N">NAV1.4 Voltage-Gated Sodium Channel</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069458" MajorTopicYN="N">Ranolazine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D026941" MajorTopicYN="N">Sodium Channel Blockers</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061567" MajorTopicYN="N">Voltage-Gated Sodium Channel Blockers</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">management</Keyword>
        <Keyword MajorTopicYN="Y">myotonia congenita</Keyword>
        <Keyword MajorTopicYN="Y">nondystrophic myotonias</Keyword>
        <Keyword MajorTopicYN="Y">paramyotonia congenita</Keyword>
        <Keyword MajorTopicYN="Y">skeletal muscle channelopathies</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32270509</ArticleId>
        <ArticleId IdType="mid">NIHMS1699383</ArticleId>
        <ArticleId IdType="pmc">PMC8117169</ArticleId>
        <ArticleId IdType="doi">10.1002/mus.26887</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Koch MC, Steinmeyer K, Lorenz C, et al.
The skeletal muscle chloride channel in dominant and recessive human myotonia. Science. 1992; 257:797–800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1379744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McClatchey AI, Van den Bergh P, Pericak-Vance MA, et al.
Temperature-sensitive mutations in the III-IV cytoplasmic loop region of the skeletal muscle sodium channel gene in paramyotonia congenita. Cell. 1992;68:769–774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1310898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strümpell A
Tonische Krämpfe in willkürliche bewegten Muskeln (Myotonia congenita). Berl Klin Wochenchr. 1881;9:119–121.</Citation>
        </Reference>
        <Reference>
          <Citation>Erb W
Klinischen und Pathologisch-Anatomisches von der Thomsenschen Krankheit. Neurol Centralblb. 1885;13:289–194.</Citation>
        </Reference>
        <Reference>
          <Citation>Horga A, Raja Rayan DL, Matthews E, et al.
Prevalence study of genetically defined skeletal muscle channelopathies in England. Neurology. 2013;80:1472–1475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3662361</ArticleId>
            <ArticleId IdType="pubmed">23516313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stunnenberg BC, Raaphorst J, Deenen JCW, et al.
Prevalence and mutation spectrum of skeletal muscle channelopathies in the Netherlands. Neuromuscul Disord. 2018;28:402–407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29606556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trivedi JR, Bundy B, Statland J, et al.
Non-dystrophic myotonia: prospective study of objective and patient reported outcomes. Brain. 2013;136:2189–2200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3692030</ArticleId>
            <ArticleId IdType="pubmed">23771340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trip J, Drost G, Ginjaar HB, et al.
Redefining the clinical phenotypes of non-dystrophic myotonic syndromes. J Neurol Neurosurg Psychiatry. 2009;80:647–652.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19211598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Statland JM, Wang Y, Richesson R, et al.
An interactive voice response diary for patients with non-dystrophic myotonia. Muscle Nerve. 2011;44:30–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3233757</ArticleId>
            <ArticleId IdType="pubmed">21674518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trip J, de Vries J, Drost G, Ginjaar HB, van Engelen BG, Faber CG. Health status in non-dystrophic myotonias: close relation with pain and fatigue. J Neurol. 2009;256:939–947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2698970</ArticleId>
            <ArticleId IdType="pubmed">19252786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sansone VA, Ricci C, Montanari M, et al.
Measuring quality of life impairment in skeletal muscle channelopathies. Eur J Neurol. 2012; 19:1470–1476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3492909</ArticleId>
            <ArticleId IdType="pubmed">22607270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomsen J
Tonische Krämpfe in willkürlich beweglichen Muskeln in Folge von ererbter psychischer Disposition. Arch Psychiatr Nervenkr. 1876;6:702–718.</Citation>
        </Reference>
        <Reference>
          <Citation>Becker PE. Zur Frage der Heterogenie der eblichen Myotonien. Nevenartz. 1957;28:455–460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13517431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Becker PE. Die Heterogenitat der Myotonien. In: Proc. 2nd Int. Congr. Human Genetics. Amsterdam: Excerpta Med, 1963, vol 3, p. 1547–1552.</Citation>
        </Reference>
        <Reference>
          <Citation>Heatwole CR, Moxley RT III. The nondystrophic myotonias. Neurotherapeutics. 2007;4:238–251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17395134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eulenberg A
Über eine familiäre, durch 6 Generationen verfolgbare congenitaler Paramyotonia. Neurol Centralblb. 1886;12:265–272.</Citation>
        </Reference>
        <Reference>
          <Citation>Cannon SC. Channelopathies of skeletal muscle excitability. Compr Physiol. 2015;5:761–790.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4754081</ArticleId>
            <ArticleId IdType="pubmed">25880512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ricker K, Moxley RT III, Heine R, Lehmann-Horn F. Myotonia fluctuans. A third type of muscle sodium channel disease. Arch Neurol. 1994;51:1095–1102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7980103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colding-Jorgensen E, Duno M, Vissing J. Autosomal dominant monosymptomatic myotonia permanens. Neurology. 2006;67:153–155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16832098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trudell RG, Kaiser KK, Griggs RC. Acetazolamide-responsive myotonia congenita. Neurology. 1987;37:488–491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3822145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rudel R, Ricker K, Lehmann-Horn F. Genotype-phenotype correlations in human skeletal muscle sodium channel diseases. Arch Neurol. 1993;50:1241–1248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8215982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ptacek LJ, Tawil R, Griggs RC, et al.
Sodium channel mutations in acetazolamide-responsive myotonia congenita, paramyotonia congenita, and hyperkalemic periodic paralysis. Neurology. 1994;44: 1500–1503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8058156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matthews E, Guet A, Mayer M, et al.
Neonatal hypotonia can be a sodium channelopathy: recognition of a new phenotype. Neurology. 2008;71:1740–1742.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2676969</ArticleId>
            <ArticleId IdType="pubmed">19015492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaharieva IT, Thor MG, Oates EC, et al.
Loss-of-function mutations in SCN4A cause severe foetal hypokinesia or ‘classical’ congenital myopathy. Brain. 2016;139:674–691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4766374</ArticleId>
            <ArticleId IdType="pubmed">26700687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsujino A, Maertens C, Ohno K, et al.
Myasthenic syndrome caused by mutation of the SCN4A sodium channel. Proc Natl Acad Sci U S A. 2003;100:7377–7382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC165883</ArticleId>
            <ArticleId IdType="pubmed">12766226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnold WD, Feldman DH, Ramirez S, et al.
Defective fast inactivation recovery of Nav 1.4 in congenital myasthenic syndrome. Ann Neurol. 2015;77:840–850.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4510994</ArticleId>
            <ArticleId IdType="pubmed">25707578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Statland JM, Fontaine B, Hanna MG, et al.
Review of the diagnosis and treatment of periodic paralysis. Muscle Nerve. 2018;57:522–530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5867231</ArticleId>
            <ArticleId IdType="pubmed">29125635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hopkins PM. Skeletal muscle physiology. Contin Educ Anaesth Crit Care Pain. 2006;6:1–6.</Citation>
        </Reference>
        <Reference>
          <Citation>Lipicky RJ, Bryant SH. Sodium, potassium, and chloride fluxes in intercostal muscle from normal goats and goats with hereditary myotonia. J Gen Physiol. 1966;50:89–111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2225635</ArticleId>
            <ArticleId IdType="pubmed">5971035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lipicky RJ, Bryant SH, Salmon JH. Cable parameters, sodium, potassium, chloride, and water content, and potassium efflux in isolated external intercostal muscle of normal volunteers and patients with myotonia congenita. J Clin Invest. 1971;50:2091–2103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC292143</ArticleId>
            <ArticleId IdType="pubmed">4940295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furman RE, Barchi RL. The pathophysiology of myotonia produced by aromatic carboxylic acids. Ann Neurol. 1978;4:357–365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">727740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adrian RH, Bryant SH. On the repetitive discharge in myotonic muscle fibres. J Physiol. 1974;240:505–515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1331026</ArticleId>
            <ArticleId IdType="pubmed">4420758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burge JA, Hanna MG. Novel insights into the pathomechanisms of skeletal muscle channelopathies. Curr Neurol Neurosci Rep. 2012;12: 62–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22083238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lehmann-Horn F, Jurkat-Rott K. Voltage-gated ion channels and hereditary disease. Physiol Rev. 1999;79:1317–1372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10508236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hawash AA, Voss AA, Rich MM. Inhibiting persistent inward sodium currents prevents myotonia. Ann Neurol. 2017;82:385–395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5639374</ArticleId>
            <ArticleId IdType="pubmed">28833464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pusch M
Myotonia caused by mutations in the muscle chloride channel gene CLCN1. Hum Mutat. 2002;19:423–434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11933197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pusch M, Steinmeyer K, Koch MC, Jentsch TJ. Mutations in dominant human myotonia congenita drastically alter the voltage dependence of the CIC-1 chloride channel. Neuron. 1995;15: 1455–1463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8845168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saviane C, Conti F, Pusch M. The muscle chloride channel ClC-1 has a double-barreled appearance that is differentially affected in dominant and recessive myotonia. J Gen Physiol. 1999;113:457–468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2222904</ArticleId>
            <ArticleId IdType="pubmed">10051520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vindas-Smith R, Fiore M, Vasquez M, et al.
Identification and functional characterization of CLCN1 mutations found in nondystrophic myotonia patients. Hum Mutat. 2016;37:74–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26510092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lossin C, George AL Jr. Myotonia congenita. Adv Genet. 2008;63: 25–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19185184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang CY, Chen TY. Physiology and pathophysiology of CLC-1: mechanisms of a chloride channel disease, myotonia. J Biomed Biotechnol. 2011;2011:685328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3237021</ArticleId>
            <ArticleId IdType="pubmed">22187529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lehmann-Horn F, Rudel R. Hereditary nondystrophic myotonias and periodic paralyses. Curr Opin Neurol. 1995;8:402–410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8542048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skov M, Riisager A, Fraser JA, Nielsen OB, Pedersen TH. Extracellular magnesium and calcium reduce myotonia in ClC-1 inhibited rat muscle. Neuromuscul Disord. 2013;23:489–502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23623567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ulbricht W
The effect of veratridine on excitable membranes of nerve and muscle. Ergeb Physiol. 1969;61:18–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4903416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lehmann-Horn F, Rudel R, Dengler R, Lorkovic H, Haass A, Ricker K. Membrane defects in paramyotonia congenita with and without myotonia in a warm environment. Muscle Nerve. 1981;4:396–406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6270549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lehmann-Horn F, Rudel R, Ricker K, Lorkovic H, Dengler R, Hopf HC. Two cases of adynamia episodica hereditaria: in vitro investigation of muscle cell membrane and contraction parameters. Muscle Nerve. 1983;6:113–121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6304507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cannon SC. Pathomechanisms in channelopathies of skeletal muscle and brain. Annu Rev Neurosci. 2006;29:387–415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16776591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cannon SC. Sodium channelopathies of skeletal muscle. Handb Exp Pharmacol. 2018;246:309–330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5866235</ArticleId>
            <ArticleId IdType="pubmed">28939973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ptacek LJ, George AL Jr, Griggs RC, et al.
Identification of a mutation in the gene causing hyperkalemic periodic paralysis. Cell. 1991;67: 1021–1027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1659948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojas CV, Wang JZ, Schwartz LS, Hoffman EP, Powell BR, Brown RH Jr. A Met-to-Val mutation in the skeletal muscle Na+ channel alpha-subunit in hyperkalaemic periodic paralysis. Nature. 1991;354:387–389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1659668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ptacek LJ, George AL Jr, Barchi RL, et al.
Mutations in an S4 segment of the adult skeletal muscle sodium channel cause paramyotonia congenita. Neuron. 1992;8:891–897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1316765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lerche H, Heine R, Pika U, et al.
Human sodium channel myotonia: slowed channel inactivation due to substitutions for a glycine within the III-IV linker. J Physiol. 1993;470:13–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1143902</ArticleId>
            <ArticleId IdType="pubmed">8308722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang N, Ji S, Zhou M, et al.
Sodium channel mutations in paramyotonia congenita exhibit similar biophysical phenotypes in vitro. Proc Natl Acad Sci U S A. 1994;91:12785–12789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC45524</ArticleId>
            <ArticleId IdType="pubmed">7809121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matthews E, Tan SV, Fialho D, et al.
What causes paramyotonia in the United Kingdom? Common and new SCN4A mutations revealed. Neurology. 2008;70:50–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18166706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Statland J, Phillips L, Trivedi JR. Muscle channelopathies. Neurol Clin. 2014;32:801–815. x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25037091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orrell RW, Jurkat-Rott K, Lehmann-Horn F, Lane RJ. Familial cramp due to potassium-aggravated myotonia. J Neurol Neurosurg Psychiatry. 1998;65:569–572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2170305</ArticleId>
            <ArticleId IdType="pubmed">9771789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basu A, Nishanth P, Ifaturoti O. Pregnancy in women with myotonia congenita. Int J Gynaecol Obstet. 2009;106:62–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19368920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phillips L, Trivedi JR. Skeletal muscle channelopathies. Neurotherapeutics. 2018;15:954–965.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6277285</ArticleId>
            <ArticleId IdType="pubmed">30341599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fontaine B
Periodic paralysis, myotonia congenita and sarcolemmal ion channels: a success of the candidate gene approach. Neuromuscul Disord. 1993;3:101–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7689379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller TM, Dias da Silva MR, Miller HA, et al.
Correlating phenotype and genotype in the periodic paralyses. Neurology. 2004;63: 1647–1655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15534250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bednarz M, Stunnenberg BC, Kusters B, et al.
A novel Ile1455Thr variant in the skeletal muscle sodium channel alpha-subunit in a patient with a severe adult-onset proximal myopathy with electrical myotonia and a patient with mild paramyotonia phenotype. Neuromuscul Disord. 2017;27:175–182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28024841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taminato T, Mori-Yoshimura M, Miki J, et al.
Paramyotonia congenita with persistent distal and facial muscle weakness: a case report with literature review. J Neuromuscul Dis. 2020;7(2):193–201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32083589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matthews E, Silwal A, Sud R, et al.
Skeletal muscle channelopathies: rare disorders with common pediatric symptoms. J Pediatr. 2017; 188:181–185.e186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28662944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bandschapp O, Iaizzo PA. Pathophysiologic and anesthetic considerations for patients with myotonia congenita or periodic paralyses. Paediatr Anaesth. 2013;23:824–833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23802937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farbu E, Softeland E, Bindoff LA. Anaesthetic complications associated with myotonia congenita: case study and comparison with other myotonic disorders. Acta Anaesthesiol Scand. 2003;47:630–634.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12699527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bissay V, Van Malderen SC, Keymolen K, et al.
SCN4A variants and Brugada syndrome: phenotypic and genotypic overlap between cardiac and skeletal muscle sodium channelopathies. Eur J Hum Genet. 2016;24:400–407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4755372</ArticleId>
            <ArticleId IdType="pubmed">26036855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matthews E, Fialho D, Tan SV, et al.
The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. Brain. 2010;133:9–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2801326</ArticleId>
            <ArticleId IdType="pubmed">19917643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stunnenberg BC, Drost G. Teaching video neuroimages: lid lag sign and diplopia in paramyotonia congenita. Neurology. 2014;83:e68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25074897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du H, Grob SR, Zhao L, et al.
Myotonia congenita with strabismus in a large family with a mutation in the SCN4A gene. Eye (Lond). 2012; 26:1039–1043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3420053</ArticleId>
            <ArticleId IdType="pubmed">22653516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trip J, Drost G, Verbove DJ, et al.
In tandem analysis of CLCN1 and SCN4A greatly enhances mutation detection in families with nondystrophic myotonia. Eur J Hum Genet. 2008;16:921–929.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18337730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cleland JC, Logigian EL. Clinical evaluation of membrane excitability in muscle channel disorders: potential applications in clinical trials. Neurotherapeutics. 2007;4:205–215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17395130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leiden Open Variation Database. https://databases.lovd.nl/shared/genes/SCN4A. Accessed
April 13, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Leiden Open Variation Database. https://databases.lovd.nl/shared/genes/CLCN1. Accessed
April 13, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Manousakis G, Al-Lozi M. Miller TM. AANEM Monogr: Differential diagnosis of myotonic disorders; 2012.</Citation>
        </Reference>
        <Reference>
          <Citation>Drost G, Stunnenberg BC, Trip J, et al.
Myotonic discharges discriminate chloride from sodium muscle channelopathies. Neuromuscul Disord. 2015;25:73–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25454733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Logigian EL, Ciafaloni E, Quinn LC, et al.
Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy. Muscle Nerve. 2007;35:479–485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17230537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghosh PS, Sorenson EJ. Use of clinical and electrical myotonia to differentiate childhood myopathies. J Child Neurol. 2015;30:1300–1306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25637645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Milone M, Batish SD, Daube JR. Myotonic dystrophy type 2 with focal asymmetric muscle weakness and no electrical myotonia. Muscle Nerve. 2009;39:383–385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19208413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young NP, Daube JR, Sorenson EJ, Milone M. Absent, unrecognized, and minimal myotonic discharges in myotonic dystrophy type 2. Muscle Nerve. 2010;41:758–762.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20513102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hobson-Webb LD, Dearmey S, Kishnani PS. The clinical and electrodiagnostic characteristics of Pompe disease with post-enzyme replacement therapy findings. Clin Neurophysiol. 2011;122: 2312–2317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21570905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanisch F, Kraya T, Kornhuber M, Zierz S. Diagnostic impact of myotonic discharges in myofibrillar myopathies. Muscle Nerve. 2013;47: 845–848.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23605961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Milone M, McEvoy KM, Sorenson EJ, Daube JR. Myotonia associated with caveolin-3 mutation. Muscle Nerve. 2012;45:897–900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22581547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hehir MK, Logigian EL. Electrodiagnosis of myotonic disorders. Phys Med Rehabil Clin N Am. 2013;24:209–220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23177040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joundi RA, Israelian G, Ghavanini A, Kassardjian CD. Myotonic discharges in anti-MuSK myasthenia. Can J Neurol Sci. 2018;45: 707–708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30210011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venables GS, Bates D, Shaw DA. Hypothyroidism with true myotonia. J Neurol Neurosurg Psychiatry. 1978;41:1013–1015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC493215</ArticleId>
            <ArticleId IdType="pubmed">712368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blomberg LH. Dystrophia myotonica probably caused by chloroquine. Acta Neurol Scand Suppl. 1965;13(Pt 2):647–651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5214341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dromgoole SH, Campion DS, Peter JB. Myotonia induced by clofibrate and sodium chlorophenoxy isobutyrate. Biochem Med. 1975; 14:238–240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1220706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwiecinski H
Myotonia induced with clofibrate in rats. J Neurol. 1978;219:107–116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">81288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwiecinski H
Myotonia induced by chemical agents. Crit Rev Toxicol. 1981;8:279–310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7026172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pierno S, De Luca A, Tricarico D, et al.
Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. J Pharmacol Exp Ther. 1995;275:1490–1496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8531120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramsey RB, McGarry JD, Fischer VW, Sarnat HB. Alteration of developing and adult rat muscle membranes by zuclomiphene and other hypocholesterolemic agents. Acta Neuropathol. 1978;44: 15–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">81585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rutkove SB, De Girolami U, Preston DC, et al.
Myotonia in colchicine myoneuropathy. Muscle Nerve. 1996;19:870–875.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8965841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonoda Y, Gotow T, Kuriyama M, Nakahara K, Arimura K, Osame M. Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors. Muscle Nerve. 1994;17:891–897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8041396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katirji B
Peripheral nerve hyperexcitability. Handb Clin Neurol. 2019; 161:281–290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31307606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Streib EW, Sun SF, Yarkowski T. Transient paresis in myo-tonic syndromes: a simplified electrophysiologic approach. Muscle Nerve. 1982;5:719–723.</Citation>
        </Reference>
        <Reference>
          <Citation>Fournier E, Arzel M, Sternberg D, et al.
Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol. 2004;56:650–661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15389891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fournier E, Viala K, Gervais H, et al.
Cold extends electromyography distinction between ion channel mutations causing myotonia. Ann Neurol. 2006;60:356–365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16786525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan SV, Matthews E, Barber M, et al.
Refined exercise testing can aid DNA-based diagnosis in muscle channelopathies. Ann Neurol. 2011;69:328–340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3051421</ArticleId>
            <ArticleId IdType="pubmed">21387378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuntzer T, Flocard F, Vial C, et al.
Exercise test in muscle channelopathies and other muscle disorders. Muscle Nerve. 2000;23: 1089–1094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10883004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McManis PG, Lambert EH, Daube JR. The exercise test in periodic paralysis. Muscle Nerve. 1986;9:704–710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3785281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heatwole CR, Statland JM, Logigian EL. The diagnosis and treatment of myotonic disorders. Muscle Nerve. 2013;47:632–648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23536309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suominen T, Schoser B, Raheem O, et al.
High frequency of co-segregating CLCN1 mutations among myotonic dystrophy type 2 patients from Finland and Germany. J Neurol. 2008;255: 1731–1736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4079033</ArticleId>
            <ArticleId IdType="pubmed">18807109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun C, Van Ghelue M, Tranebjaerg L, Thyssen F, Nilssen O, Torbergsen T. Myotonia congenita and myotonic dystrophy in the same family: coexistence of a CLCN1 mutation and expansion in the CNBP (ZNF9) gene. Clin Genet. 2011;80:574–580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21204798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bugiardini E, Rivolta I, Binda A, et al.
SCN4A mutation as modifying factor of myotonic dystrophy type 2 phenotype. Neuromuscul Disord. 2015;25:301–307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25660391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mathur N, Ghosh PS. Schwartz-Jampel Syndrome. Pediatr Neurol. 2017;68:77–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28129933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Padmanabha H, Mathew T, Manjusha T. Schwartz-Jampel Syndrome Mimicking Myotonia Congenita. Neurol India. 2019;67(4):1160–1162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31512670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller TM. Differential diagnosis of myotonic disorders. Muscle Nerve. 2008;37:293–299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18067134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braz L, Soares-Dos-Reis R, Seabra M, Silveira F, Guimaraes J. Brody disease: when myotonia is not myotonia. Pract Neurol. 2019;19: 417–419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30996034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torbergsen T
Rippling muscle disease: a review. Muscle Nerve Suppl. 2002;11:S103–S107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12116294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sawlani K, Katirji B. Peripheral nerve hyperexcitability syndromes. Continuum (Minneap Minn). 2017;23:1437–1450.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28968370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed A, Simmons Z. Isaacs syndrome: a review. Muscle Nerve. 2015;52:5–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25736532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bloem BR, Voermans NC, Aerts MB, Bhatia KP, van Engelen BG, van de Warrenburg BP. The wrong end of the telescope: neuromuscular mimics of movement disorders (and vice versa). Pract Neurol. 2016; 16:264–269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26965497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trip J, Pillen S, Faber CG, van Engelen BG, Zwarts MJ, Drost G. Muscle ultrasound measurements and functional muscle parameters in non-dystrophic myotonias suggest structural muscle changes. Neuromuscul Disord. 2009;19:462–467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19540760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morrow JM, Matthews E, Raja Rayan DL, et al.
Muscle MRI reveals distinct abnormalities in genetically proven non-dystrophic myotonias. Neuromuscul Disord. 2013;23:637–646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3744809</ArticleId>
            <ArticleId IdType="pubmed">23810313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Statland JM, Bundy BN, Wang Y, et al.
Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA. 2012;308:1357–1365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3564227</ArticleId>
            <ArticleId IdType="pubmed">23032552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stunnenberg BC, Raaphorst J, Groenewoud HM, et al.
Effect of mexiletine on muscle stiffness in patients with nondystrophic myotonia evaluated using aggregated N-of-1 trials. JAMA. 2018; 320:2344–2353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6583079</ArticleId>
            <ArticleId IdType="pubmed">30535218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andersen G, Hedermann G, Witting N, Duno M, Andersen H, Vissing J. The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. Brain. 2017;140:2295–2305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29050397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suetterlin KJ, Bugiardini E, Kaski JP, et al.
Long-term safety and efficacy of mexiletine for patients with skeletal muscle channelopathies. JAMA Neurol. 2015;72:1531–1533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26658970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lorusso S, Kline D, Bartlett A, et al.
Open-label trial of ranolazine for the treatment of paramyotonia congenita. Muscle Nerve. 2019;59: 240–243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6340713</ArticleId>
            <ArticleId IdType="pubmed">30390395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnold WD, Kline D, Sanderson A, et al.
Open-label trial of ranolazine for the treatment of myotonia congenita. Neurology. 2017;89:710–713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5562961</ArticleId>
            <ArticleId IdType="pubmed">28710329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Novak KR, Norman J, Mitchell JR, Pinter MJ, Rich MM. Sodium channel slow inactivation as a therapeutic target for myotonia congenita. Ann Neurol. 2015;77:320–332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4315705</ArticleId>
            <ArticleId IdType="pubmed">25515836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwiecinski H, Ryniewicz B, Ostrzycki A. Treatment of myotonia with antiarrhythmic drugs. Acta Neurol Scand. 1992;86:371–375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1455983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skov M, de Paoli FV, Nielsen OB, Pedersen TH. The anti-convulsants lacosamide, lamotrigine, and rufinamide reduce myotonia in isolated human and rat skeletal muscle. Muscle Nerve. 2017;56:136–142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27783415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griggs RC, Moxley RT III, Riggs JE, Engel WK. Effects of acetazolamide on myotonia. Ann Neurol. 1978;3:531–537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">677818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eguchi H, Tsujino A, Kaibara M, et al.
Acetazolamide acts directly on the human skeletal muscle chloride channel. Muscle Nerve. 2006;34: 292–297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16770776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sansone VA, Burge J, McDermott MP, et al.
Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis. Neurology. 2016;86:1408–1416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4831040</ArticleId>
            <ArticleId IdType="pubmed">26865514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Milner-Brown HS, Miller RG. Myotonic dystrophy: quantification of muscle weakness and myotonia and the effect of amitriptyline and exercise. Arch Phys Med Rehabil. 1990;71:983–987.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2241546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonini G, Vichi R, Leardi MG, Pennisi E, Monza GC, Millefiorini M. Effect of clomipramine on myotonia: a placebo-controlled, double-blind, crossover trial. Neurology. 1990;40:1473–1474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2202927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bissay V, Keymolen K, Lissens W, Laureys G, Schmedding E, De Keyser J. Late onset painful cold-aggravated myotonia: three families with SCN4A L1436P mutation. Neuromuscul Disord. 2011;21: 590–593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21664816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Durelli L, Mutani R, Fassio F. The treatment of myotonia: evaluation of chronic oral taurine therapy. Neurology. 1983;33:599–603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6341873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grant R, Sutton DL, Behan PO, Ballantyne JP. Nifedipine in the treatment of myotonia in myotonic dystrophy. J Neurol Neurosurg Psychiatry. 1987;50:199–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1031492</ArticleId>
            <ArticleId IdType="pubmed">3553433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dressler D, Adib SF. Botulinum toxin in myotonia congenita: it does not help against rigidity and pain. J Neural Transm. 2014;121: 531–532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24357052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leyburn P, Walton JN. The treatment of myotonia: a controlled clinical trial. Brain. 1959;82:81–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13651495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markhorst JM, Stunnenberg BC, Ginjaar IB, Drost G, Erasmus CE, Sie LT. Clinical experience with long-term acetazolamide treatment in children with nondystrophic myotonias: a three-case report. Pediatr Neurol. 2014;51:537–541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25042881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohtaki E, Komori H, Yamaguchi Y, Matsuishi T. Successful dantrolene sodium treatment of a patient with myotonia congenita (Thomsen’s disease). Acta Paediatr Jpn. 1991;33:668–671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1799124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ceccarelli M, Rossi B, Siciliano G, Calevro L, Tarantino E. Clinical and electrophysiological reports in a case of early onset myotonia congenita (Thomsen’s disease) successfully treated with mexiletine. Acta Paediatr. 1992;81:453–455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1498517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheela SR. Myotonia congenita: response to carbamazepine. Indian Pediatr. 2000;37:1122–1125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11042715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caietta E, Milh M, Sternberg D, et al.
Diagnosis and outcome of SCN4A-related severe neonatal episodic laryngospasm (SNEL): 2 new cases. Pediatrics. 2013;132:e784–e787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23958773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Portaro S, Rodolico C, Sinicropi S, Musumeci O, Valenzise M, Toscano A. Flecainide-responsive myotonia permanens with SNEL onset: a new case and literature review. Pediatrics. 2016;137: pii: e20153289, e1–e6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26944947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cavalli M, Fossati B, Vitale R, et al.
Flecainide-Induced Brugada Syndrome in a patient with skeletal muscle sodium channelopathy: a case report with critical therapeutical implications and review of the literature. Front Neurol. 2018;9:385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5988887</ArticleId>
            <ArticleId IdType="pubmed">29899727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imbrici P, Altamura C, Pessia M, Mantegazza R, Desaphy JF, Camerino DC. ClC-1 chloride channels: state-of-the-art research and future challenges. Front Cell Neurosci. 2015;9:156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4410605</ArticleId>
            <ArticleId IdType="pubmed">25964741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Desaphy JF, Costanza T, Carbonara R, Conte CD. In vivo evaluation of antimyotonic efficacy of beta-adrenergic drugs in a rat model of myotonia. Neuropharmacology. 2013;65:21–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3546166</ArticleId>
            <ArticleId IdType="pubmed">23000075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Bellis M, Camerino DC, Desaphy JF. Toward precision medicine in myotonic syndromes. Oncotarget. 2017;8:14279–14280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5362403</ArticleId>
            <ArticleId IdType="pubmed">28199958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Desaphy JF, Carbonara R, D’Amico A, et al.
Translational approach to address therapy in myotonia permanens due to a new SCN4A mutation. Neurology. 2016;86:2100–2108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4891212</ArticleId>
            <ArticleId IdType="pubmed">27164696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andersen G, Lokken N, Vissing J. Aerobic training in myotonia congenita: effect on myotonia and fitness. Muscle Nerve. 2017;56:696–699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28039888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parness J, Bandschapp O, Girard T. The myotonias and susceptibility to malignant hyperthermia. Anesth Analg. 2009;109:1054–1064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19762732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snyder Y, Donlin-Smith C, Snyder E, Pressman E, Ciafaloni E. The course and outcome of pregnancy in women with nondystrophic myotonias. Muscle Nerve. 2015;52:1013–1015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25900207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gregg AR, Tomich PG. Mexilitene use in pregnancy. J Perinatol. 1988;8:33–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3236091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Falardeau J, Lobb BM, Golden S, Maxfield SD, Tanne E. The use of acetazolamide during pregnancy in intracranial hypertension patients. J Neuroophthalmol. 2013;33:9–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22635167</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
